SCHEDULE: Goldman Sachs Reports Minimal Stake in Transcode Therapeutics
Beneficial Ownership Report
Goldman Sachs Group and its subsidiary reported a 0.0% beneficial ownership in Transcode Therapeutics Inc. common stock as of September 30, 2025.
Summary
- The Goldman Sachs Group, Inc. and its subsidiary, Goldman Sachs & Co. LLC, filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in TRANSCODE THERAPEUTICS INC.
- As of September 30, 2025, the reporting persons collectively beneficially owned 82 shares of Transcode Therapeutics Inc. common stock.
- This ownership represents 0.0% of the class of securities.
- Goldman Sachs & Co. LLC holds shared voting and shared dispositive power over these 82 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: Neutral. This is a routine regulatory filing disclosing a very small, passive ownership stake by a major financial institution. It provides no positive or negative operational or financial news about the issuer.
Positives
- Goldman Sachs Group and its subsidiary are adhering to regulatory disclosure requirements by filing this Schedule 13G.
- The filing explicitly states that the securities were acquired and are held in the ordinary course of business, not for control purposes, indicating a passive investment.
Negatives
- The reported beneficial ownership of 0.0% of the class of securities is negligible and does not indicate a significant investment or confidence from Goldman Sachs in Transcode Therapeutics Inc.
Future Outlook
Not applicable, as this filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance from the issuer or reporting persons regarding the issuer's future performance.
Industry Context
This filing is a routine disclosure of institutional ownership and does not provide specific insights into broader industry trends or competitive landscape for Transcode Therapeutics Inc. It merely indicates a minimal, passive investment by a major financial institution.
Stakeholder Impact
- Shareholders: Minimal impact due to the negligible ownership stake reported by Goldman Sachs. It does not signal significant institutional interest or divestment.
Key Dates
| Date | Description |
|---|---|
| 2024-07-29 | Previous Power of Attorney granted by The Goldman Sachs Group, Inc. superseded. |
| 2024-10-01 | Previous Power of Attorney granted by Goldman Sachs & Co. LLC superseded. |
| 2025-07-16 | Effective date of new Power of Attorney for The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC. |
| 2025-09-30 | Date of event requiring the filing of this statement (beneficial ownership calculation date). |
| 2025-10-08 | Date of filing of the Schedule 13G Amendment No. 1. |
| 2026-07-16 | Expiration date of the current Power of Attorney unless earlier revoked. |
Keywords
Goldman Sachs, Transcode Therapeutics, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.